Local Registry of Central Nervous System Infections (ReCeNSI)
ReCeNSI
1 other identifier
observational
520
1 country
1
Brief Summary
Central Nervous System (CNS) infections are considered rare conditions but at the same time, they are emergencies whose diagnosis and treatment are time-dependent. They include several clinical syndromes, including meningitis, encephalitis, brain abscesses, and post-surgical meningitis. The classic triad of symptoms includes fever, altered mental status, and neck stiffness, but other common manifestations include nausea and vomiting, cranial nerve dysfunction, skin rash, and seizures. Due to the potentially life-threatening effects on patients, these clinical conditions cannot be underestimated. The CNS includes the brain and spinal cord, surrounded and protected by the meninges and cerebrospinal fluid (CSF). Within the CNS are numerous nuclei responsible for vital functions, as well as more complex intellectual activities.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Mar 2022
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
March 4, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 5, 2022
CompletedFirst Submitted
Initial submission to the registry
December 19, 2025
CompletedFirst Posted
Study publicly available on registry
January 23, 2026
CompletedStudy Completion
Last participant's last visit for all outcomes
January 1, 2030
ExpectedJanuary 23, 2026
September 1, 2025
1 day
December 19, 2025
January 21, 2026
Conditions
Outcome Measures
Primary Outcomes (1)
To evaluate the outcome in terms of mortality at discharge in patients with CNS infections.
From January 2012
Eligibility Criteria
In the nine years since 2012, we have identified 260 patients with positive CSF tests. We assume that over the next 10 years we will register the same number of patients, for a total of 520 patients. With this sample size, the precision of the mortality estimate over the study period will be at worst ±4.3%, corresponding to half the 95% confidence interval (CI) of a 50% chance. If the mortality rate were 10%, the precision would be ±2.7%; if the mortality rate were 5%, the precision would be ±2%.
Contact the study team to discuss eligibility requirements. They can help determine if this study is right for you.
Sponsors & Collaborators
Study Sites (1)
Fondazione IRCCS Policlinico San Matteo di Pavia
Pavia, Italia, 27100, Italy
MeSH Terms
Conditions
Study Design
- Study Type
- observational
- Observational Model
- OTHER
- Time Perspective
- OTHER
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Principal Investigator
Study Record Dates
First Submitted
December 19, 2025
First Posted
January 23, 2026
Study Start
March 4, 2022
Primary Completion
March 5, 2022
Study Completion (Estimated)
January 1, 2030
Last Updated
January 23, 2026
Record last verified: 2025-09